Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Real-time Estimate Cboe BZX Other stock markets 19:41:05 16/01/2025 GMT			5-day change	1st Jan Change
4.355 ^USD	-2.13%		-5.54%	-9.29%

01-08	Vanda Pharmaceuticals Highlights Issues in Gastroparesis Treatment Application Review in Letter to FDA Commissioner	MT
12-20	Vanda Pharmaceuticals' Prospective Treatment for Blood Cancer Receives US FDA's Orphan Drug Designation	MT

Vanda Pharmaceuticals Inc., Q2 2021 Earnings Call, Jul 28, 2021

July 28, 2021 at 09:30 pm

Presentation Operator Message
Operator (Operator)

Good day, and thank you for standing by. Welcome to the Vanda Pharmaceuticals Inc. Second Quarter 2021 Earnings Conference Call. [Operator

This article is reserved for subscribers

To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Highlights Issues in Gastroparesis Treatment Application Review in Letter to FDA Commissioner	01-08	MT
Vanda Pharmaceuticals' Prospective Treatment for Blood Cancer Receives US FDA's Orphan Drug Designation	12-20	MT
Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q3 Revenue $47.7M	11-06	MT
Vanda Pharmaceuticals Inc., Q3 2024 Earnings Call, Nov 06, 2024	11-06
Vanda Pharmaceuticals Inc. Revises Revenue Guidance for the Full Year 2024	11-06	CI
Vanda Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-06	CI
HC Wainwright Starts Vanda Pharmaceuticals With Buy Rating, $18 Price Target	31/10/24	MT
Global markets live: InPost, Nvidia, Coty, Verizon, Apple...	15/10/24
Sector Update: Health Care Stocks Rise Late Afternoon	14/10/24	MT
Sector Update: Health Care Stocks Higher Monday Afternoon	14/10/24	MT
Vanda Pharmaceuticals Shares Rise; Cycle Pharmaceuticals' Buyout Offer Rejected Again	14/10/24	MT
Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer	14/10/24	RE
Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA for approximately $490 million.	13/10/24	CI
Vanda Pharma Shares Fall 15% as FDA Denies Approval of Tradipitant NDA for Treating Gastroparesis Symptoms	19/09/24	MT
U.S. FDA declines to approve Vanda's stomach paralysis drug	19/09/24	RE
Top Premarket Decliners	19/09/24	MT
FDA Rejects Vanda Pharma's Application for Gastroparesis Drug Tradipitant	19/09/24	DJ
FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis	19/09/24	CI
FDA Decision Due on Vanda Pharma's Gastroparesis Drug	18/09/24	DJ
Vanda Pharmaceuticals Inc., Q2 2024 Earnings Call, Jul 31, 2024	31/07/24
Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q2 Revenue $50.5M, vs. Street Est of $47.9M	31/07/24	MT
Vanda Pharmaceuticals Inc. Reinstates Financial Guidance for the Full Year 2024	31/07/24	CI
Vanda Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	31/07/24	CI
Cantor Fitzgerald Initiates Vanda Pharmaceuticals at Overweight With $11 Price Target	11/07/24	MT
Vanda Pharmaceuticals Says Federal Court Allows Patent Lawsuit Over Hetlioz	01/07/24	MT